Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions
AtherosclerosisHIV Infections
Interventions
DRUG

Rosuvastatin

10 mg/day rosuvastatin

DRUG

Placebo

Placebo, 10 mg a day for 96 weeks

Trial Locations (1)

V6Z 1Y6

The St. Paul's Hospital HIV Metabolic Clinic & The BC Centre for Excellence in HIV/AIDS, Vancouver

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

CIHR Canadian HIV Trials Network

NETWORK

lead

University of British Columbia

OTHER